JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.28 -5.39

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.26

Max

2.32

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+375.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. märts 2026

Turustatistika
By TradingEconomics
Turukapital	69M 616M
Eelmine avamishind	7.67
Eelmine sulgemishind	2.28

Uudiste sentiment

By Acuity

65%

35%

314 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. jaan 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30. jaan 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30. jaan 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30. jaan 2026, 22:20 UTC

Tulu

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30. jaan 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. jaan 2026, 21:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 21:36 UTC

Tulu

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30. jaan 2026, 21:33 UTC

Tulu

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30. jaan 2026, 20:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30. jaan 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30. jaan 2026, 19:52 UTC

Tulu

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30. jaan 2026, 19:29 UTC

Market Talk

Tulu

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30. jaan 2026, 19:07 UTC

Market Talk

Canada Performing Well Below Economic Potential -- Market Talk

30. jaan 2026, 18:46 UTC

Tulu

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30. jaan 2026, 18:34 UTC

Tulu

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

375.21% tõus

12 kuu keskmine prognoos

Keskmine 11.5 USD 375.21%

Kõrge 15 USD

Madal 9 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

314 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.